Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 95-103

  Yamasaki, Y ^a   Ieiri, I ^a   Kusuhara, H ^b   Sasaki, T ^a   Kimura, M ^c   Tabuchi, H ^a   Ando, Y ^a   Irie, S ^c   Ware, J A ^d   Nakai, Y ^d   Higuchi, S ^a   Sugiyama, Y ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; N ACETYLSULFAPYRIDINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG DISPOSITION; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; MALE; MOLECULAR PROBE; NONLINEAR MIXED EFFECTS MODELLING ANALYSIS; NONLINEAR SYSTEM; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TABLET; VOLUNTEER;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; MALE; NEOPLASM PROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SULFASALAZINE;

EID: 45549106377     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100459     Document Type: Article

References (44)

1. Peppercorn, M.A. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann. Intern. Med. 101, 377-386 (1984).
2. Rains, C.P., Noble, S. & Faulds, D. Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50, 137-156 (1995).
3. Houston, J.B., Day, J. & Walker, J. Azo reduction of sulphasalazine in healthy volunteers. Br. J. Clin. Pharmacol. 14, 395-398 (1982).
4. Peppercorn, M.A. & Goldman, P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. 181, 555-562 (1972).
5. Bird, H.A. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid - which is the active moiety in rheumatoid arthritis? Br. J. Rheumatol. 34 (suppl.2), 16-19 (1995).
6. Pullar, T., Hunter, J.A. & Capell, H.A. Which component of sulphasalazine is active in rheumatoid arthritis? Br. Med. J. 290, 1535-1538 (1985).
7. Das, K.M. & Dubin, R. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 1, 406-425 (1976).
8. Das, K.M., Eastwood, M.A., McManus, J.P.A. & Sircus, W. The metabolism of salicylazosulphapyridine in ulcerative colitis I. The relationship between metabolites and the response to treatment in inpatients. Gut 14, 631-636 (1973).
9. Das, K.M., Eastwood, M.A., McManus, J.P.A. & Sircus, W. The metabolism of salicylazosulphapyridine in ulcerative colitis II. The relationship between metabolites and the progress of the disease studied in outpatients. Gut 14, 637-641 (1973).
10. Schroder, H. & Campbell, D.E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin. Pharmacol. Ther. 13, 539-551 (1972).
11. Matas, N., Thygesen, P., Stacey, M., Risch, A. & Sim, E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet. Cell Genet. 77, 290-295 (1997).
12. Abe, M., Deguchi, T. & Suzuki, T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem. Biophys. Res. Commun. 191, 811-816 (1993).
13. Deguchi, T., Mashimo, M. & Suzuki, T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265, 12757-12760 (1990).
14. Parkin, D.P. et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155, 1717-1722 (1997).
15. Okumura, K., Kita, T., Chikazawa, S., Komada, F., Iwakawa, S. & Tanigawara, Y. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin. Pharmacol. Ther. 61, 509-517 (1997).
16. Human NAT2 alleles. http://louisville.edu/medschool/pharmacology/ NAT2.html
17. Tanigawara, Y. et al. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol. Pharm. Bull. 25, 1058-1062 (2002).
18. Pounder, R.E., Craven, E.R., Henthor, J.S. & Bannatyne, J.M. Red cell abnormalities associated with sulfasalazine maintenance therapy for ulcerative colitis. Gut 16, 181-185 (1975).
19. Wadelius, M., Stjernberg, E., Wiholm, B.E. & Rane, A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10, 35-41 (2000).
20. Machida, H. et al. Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene. World J. Gastroenterol. 11, 4833-4837 (2005).
21. Cervenak, J. et al. The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett. 234, 62-72 (2006).
22. Maliepaard, M. et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464 (2001).
23. Kruijtzer, C.M., Beijnen, J.H. & Schellens, J.H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7, 516-530 (2002).
24. Taipalensuu, J. et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299, 164-170 (2001).
25. Doyle, L.A. & Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358 (2003).
26. Sparreboom, A. et al. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. 4, 650-653 (2005).
27. Sparreboom, A. et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 76, 38-44 (2004).
28. Zhang, W. et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta. 373, 99-103 (2006).
29. Zaher, H., Khan, A.A., Palandra, J., Brayman, T.G., Yu, L. & Ware, J.A. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm. 3, 55-61 (2006).
30. Li, J. et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 6, 432-438 (2007).
31. Cusatis, G. et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 98, 1739-1742 (2006).
32. Ieiri, I. et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82, 541-547 (2007).
33. Kobayashi, D. et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33, 94-101 (2005).
34. Kondo, C. et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21, 1895-1903 (2004).
35. Azad Khan, A.K., Truelove, S.C. & Aronson, J.K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br. J. Clin. Pharmacol. 13, 523-528 (1982).
36. Das, K.M., Eastwood, M.A., McManus, J.P.A. & Sircus, W. The role of the colon in the metabolism of salicylazosulphapyridine. Scand. J. Gastroenterol. 9, 137-141 (1974).
37. Kita, T. et al. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol. Pharm. Bull. 24, 1176-1180 (2001).
38. Goldman, P. & Peppercorn, M.A. Drug therapy-sulfasalazine. New Eng. J. Med. 293, 20-23 (1975).
39. Peppercorn, M.A. & Goldman, P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 64, 240-245 (1973).
40. Show, P.N., Sivner, A.L., Aarons, L. & Houston, J.B. A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma. J. Chromatogr. 274, 393-397 (1983).
41. Chungi, V.S., Rekhi, G.S. & Shargel, L. A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids. J. Pharm. Sci. 78, 235-238 (1989).
42. Beal, S.L. & Sheiner, L.B. NONMEM User's Guides. San Francisco, CA, NONMEM Project Group, University of California at San Francisco, San Francisco, CA (1998).
43. Djebli, N. et al. Sirolimus population pharmacokinetic/ pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin. Pharmacokinet. 45, 1135-1148 (2006).
44. Saint-Marcoux, F. et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin. Pharmacokinet. 45, 905-922 (2006).